Summary: Evaluated enalapril versus placebo in patients with systolic heart failure and New York Heart Association Functional (NYHA) class IV symptoms. The primary endpoint of 6-month mortality was significantly reduced with enalapril. There was a significant reduction in NYHA functional class and heart failure progression. There was no decrease in sudden cardiac death.

Original Publication:

N Engl J Med. 1987 Jun 4;316(23):1429-35.

Eponym: COoperative North Scandinavian ENalapril SUrvival Study